Clinical trials: AMI
Coronary Artery Disease
Physicians International Coronary Computed Tomography Angiography (CCTA) Utilization Registry
This protocol describes an observational study whose goal is to collect de-identified Coronary CT Angiography (CCTA) acquisition factors and interpretations (findings) from several hundred U.S.
- Trial name
- BIGPICTURE (NCT00932958)
- Where
- United States
- Volunteers
- 6,000 people
- Sponsor
- MDDX LLC
Shock, Cardiogenic, High Risk Percutaneous Coronary Interventions
Synchronized Cardiac Assist for Cardiogenic Shock
The purpose of this study is to collect prospective safety and performance information for the i-COR® device using synchronized cardiac assist in the setting of combined heart-lung failure or in high risk percutaneous…
- Trial name
- NCT02697006
- Testing
- i-cor Synchronized Cardiac Assist Device
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Xenios AG
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Myocardial Infarction
MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)
The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)
- Trial name
- MiSaver® (NCT04050163)
- Testing
- MiSaver®
- Where
- 2 sites in Taiwan
- Volunteers
- 11 people
- Sponsor
- Honya Medical Inc
Coronary Artery Disease
Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy
The purpose of this study is to determine whether or not the Angioshield device can be safely applied to support saphenous vein grafts used in standard coronary bypass surgery.
- Trial name
- NCT02072239
- Testing
- Angioshield
- Where
- Poland
- Volunteers
- 13 people
- Sponsor
- Neograft Technologies, Incorporated
Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
Comparison of Four Intensive Care Scores in Prediction of VA-ECMO Survival.
VA-ECMO is increasingly utilized in the setting of cardiogenic shock or cardiac arrest to restore hemodynamic stability and end organ function.
- Trial name
- ECMO (NCT05730881)
- Testing
- ECMO
- Where
- Qatar
- Volunteers
- 200 people
- Sponsor
- Hamad Medical Corporation
Anterior Myocardial Infarction
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
The research study is being done to see if SGC001 can be used to treat people scheduled to undergo percutaneous coronary intervention for Anterior ST-segment Elevation Myocardial Infarction.
- Trial name
- NCT07091929
- Testing
- SGC001
- Where
- 4 sites in China
- Volunteers
- 38 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Contraception, Female Contraception
A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control
The purpose of the study is to use data from a health care information database to assess the risk of venous thromboembolism (blood clots), myocardial infarction (heart attacks), and stroke among women using a transdermal…
- Trial name
- NCT00377988
- Testing
- Transdermal Contraceptive System, Norgestimate-containing oral contraceptives with EE
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes Mellitus
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
- Trial name
- SAVOR- TIMI 53 (NCT01107886)
- Testing
- Saxagliptin
- Where
- 536 sites in United States, Argentina and 25 more
- Volunteers
- 18,206 people
- Sponsor
- AstraZeneca
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360073
- Where
- 2 sites in Spain, Sweden
- Volunteers
- 42,542 people
- Sponsor
- AstraZeneca
Myocardial Infarction
Safety of TG100-115 for Heart Attack Treated With Angioplasty
TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow.
- Trial name
- NCT00103350
- Testing
- TG100-115
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- TargeGen
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline